OSRH
OSR Holdings, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.12
+0.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.8M | 2.9M | 3.5M | — | — |
| Cost of Revenue | 3.6M | 2.3M | 2.7M | — | — |
| Gross Profit | (1.8M) | 592.9K | 811.2K | — | — |
| Operating Expenses | |||||
| R&D Expense | 384.3K | 318.4K | 161.2K | — | — |
| SG&A Expense | 12.5M | 9.2M | 2.5M | 1.8M | 35.4K |
| General & Admin Expense | 11.2M | 9.2M | 2.5M | 1.8M | 35.4K |
| Selling & Marketing Expense | — | — | 2.8K | — | — |
| Other Expenses | 2.3M | 9.4M | 9.8M | — | — |
| Total Operating Expenses | 15.1M | 18.9M | 12.5M | 1.8M | 35.4K |
| Cost and Expenses | 18.7M | 21.2M | 15.2M | 1.8M | 35.4K |
| Operating Income (EBIT) | (16.9M) | (18.3M) | (11.7M) | (1.8M) | (35.4K) |
| Non-Operating | |||||
| Interest Income | 54.0K | 63.9K | 1.5M | 2.8M | — |
| Interest Expense | 496.8K | 506.2K | 43.0K | — | — |
| Net Interest Income | (442.8K) | (442.3K) | 1.4M | 2.8M | — |
| Other Non-Op Income/Expense | (744.3K) | (10.6M) | (200.5K) | 2.8M | — |
| Non-Operating Income (excl Interest) | 247.5K | 10.0M | 149.1K | (2.8M) | — |
| EBT (Pre-Tax Income) | (17.6M) | (28.9M) | (11.9M) | 944.6K | (35.4K) |
| Income Tax Expense | (891.8K) | (1.8M) | (1.6M) | 540.8K | — |
| Bottom Line | |||||
| Net Income | (15.1M) | (18.0M) | (10.3M) | 403.8K | (35.4K) |
| Earnings from Cont. Ops | (16.7M) | (27.1M) | (10.3M) | 403.8K | (35.4K) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (15.0M) | (18.0M) | (10.3M) | 403.8K | (35.4K) |
| Per Share | |||||
| Basic EPS | ($3.52) | ($4.02) | ($0.54) | $0.07 | ($0.00) |
| Diluted EPS | ($3.72) | ($4.02) | ($0.54) | $0.07 | ($0.00) |
| Revenue Per Share | $0.40 | $0.65 | $0.79 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 4.5M | 4.5M | 4.5M | 7.7M | 9.1M |
| Diluted Shares Outstanding | 4.5M | 4.5M | 4.5M | 7.7M | 9.1M |
| Profitability Metrics | |||||
| EBITDA | (7.7M) | (19.1M) | (2.2M) | 3.7M | 193.1K |
| D&A | 9.5M | 9.3M | 9.7M | 2.8M | 228.5K |
| EBIT | (17.1M) | (28.4M) | (11.8M) | 944.6K | (35.4K) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026